Investors find healthcare industry gives lower returns than other sectors
This article was originally published in Clinica
Executive Summary
Putting money into the US healthcare industry is nowhere near as profitable as investing in other sectors of business. This is the conclusion reached in a survey of the growth in share prices in the healthcare industry for the first half of the year. Improvement in stock value in the industry is dramatically down on major indices such as the Dow Jones Industrial Average, Standard & Poor's 500 and the Nasdaq Composite.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.